Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 4, 1998, Pages 540-544

  Hayek, Tony ^a   Attias, Judith ^a   Smith, Jonathan ^b   Breslow, Jan L ^b   Keidar, Shlomo ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Captopril; LDL; Oxidation; Transgenic mice

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; CAPTOPRIL; COPPER SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIPID PEROXIDATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CAPTOPRIL; CHOLESTEROL; COPPER SULFATE; FREE RADICAL SCAVENGERS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; MICE; OXIDATIVE STRESS; RANDOM ALLOCATION;

EID: 0031954806     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199804000-00011     Document Type: Article

References (41)

1. Yusuf S, Pepine CJ, Garces H. Effect of enalapril on myocardial infarction and unstable angina pectoris in patients with low ejection fractions. Lancet 1992;340:1173-9.
2. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
3. Geisterfer A, Peach M, Owens G. Angiotensin II induces hypertrophy of cultured rat aortic smooth muscle cells. Circ Res 1988;62: 749-56.
4. Campbell-Boswell M, Robertson A. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 1981;35:265-73.
5. Daemon M, Lombardi D, Bosman F, Schwartz S. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.
6. Wolf G, Haberstroh U, Neilson E. Angiotensin II stimulates the proliferation and biosynthesis of type-I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
7. Katoh H, Suzuki H, Ogata Y. Angiotensin II stimulates collagen and fibronectin synthesis in cultured vascular smooth muscle cells. Clin Exp Hypertens 1990;12:675-88.
8. Chobanian A, Handenschild C, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
9. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15:565-72.
10. Charpiot P, Rolland PH, Friggi A. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler Thromb 1993;13:1125-38.
11. Rolland PH, Souchet T, Friggi A. Angiotensin converting enzyme inhibition-induced changes in patterns of hemodynamics, aorta viscoelasticity, arterial histopathology and endothelial cholesterol fluxes of atherosclerotic minipigs. J Hypertens 1991;9:S178-9.
12. Kowala M, Grove R. Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters: fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
13. Keidar S, Oiknine J, Leiba A, Shapira C, Leiba M, Aviram M. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol 1996;27:183-6.
14. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. LDL isolated from patients with essential hypertension exhibit increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994;107:71-84.
15. Keidar S, Brook JG, Aviram M. Angiotensin II enhances lipid peroxidation of low density lipoprotein. News Physiol Sci 1993; 8:245-8.
16. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated lipid peroxidation of LDL. Atherosclerosis 1995;115:201-15.
17. Keidar S; Kaplan M; Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996;16:97-105.
18. Plump A, Smith J, Hayek T. et al. Severe hypercholesterolemia and atherosclerosis in apo E deficient mice created by homologous recombinant ES cells. Cell 1992;71:343-53.
19. Zhang SH, Reddick RL, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-71.
20. Nakashima Y, Plump A, Raines E, Breslow JL, Ross R. Apo E deficient mice develop lesions at all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-9.
21. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E: evaluation of lesional development and progression. Arterioscler Thromb 1994;14:141-8.
22. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E deficient mice. Biochem Biophys Res Commun 1994;201:1567-74.
23. Walsh A, Ito Y, Breslow JL. High levels of human apo A-I in transgenic mice result in increased plasma levels of small HDL particles comparable to human HDL3. J Biol Chem 1989;264:6488-94.
24. Holmquist B, Bunning P, Riordan J. A spectrometric assay for angiotensin converting enzyme. Anal Biochem 1979;95:540-4.
25. Lowry OH, Rosebrough NJ, Farr L, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
26. Buege L, Aust S. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
27. Maltrud K, Farbrot T, Huse A, Bredo S. Antioxidant and radical scavenging effects of arthiraquinones and anthrones. Pharmacology 1993;47:77-85.
28. Nenseter M, Halvorsen B, Rosvold Q, Rustan AC, Drevon C. Paracetamol inhibits copper ion-induced, azo compound initiated and mononuclear cell-mediated oxidative modification of LDL. Arterioscler Thromb Vas Biol 1995;15:1338-44.
29. Jackson B, Cubela RB, Johnston CI. Inhibition of tissue angiotensin converting enzyme by perindopril: in vivo assessment in the rat using radioinhibitor binding displacement. J Pharmacol Exp Ther 1988;245:950-5.
30. Cohen ML, Kurz KD. ACE inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK421. J Pharmacol Exp Ther 1982;220:63-9.
31. Goetzl E, Klickstein LB, Watt K, Wintroub B. The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun 1980;97:1097-1102.
32. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens B. Contribution of kinins to the cardiovascular actions of ACE inhibitors. Pharmacol Rev 1995;47:25-49.
33. Chopra M, Bewich H, Clapperton M, Dargie HJ, Smith W, Muway J. Antioxidant effects of angiotensin converting enzyme inhibitors: free radicals and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl and non-sulfhydryl containing ACE inhibitors. J Cardiovasc Pharmacol 1992;19:330-40.
34. Parathasarathy S, Steinberg D, Witztum JL. The role of oxidized LDL in the pathogenesis of atherosclerosis. Annu Rev Med 1992; 43:219-25.
35. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993;98:1-9.
36. Witztum JL, Steinberg D. Role of oxidized LDL in atherogenesis. J Clin Invest 1991;88:1785-91.
37. Steinberg D, Parathasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of LDL that increase its atherogenicity. N Engl J Med 1989;320:915-24.
38. Aviram M. LDL modification by cholesterol oxidase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 1992;267:218-25.
39. Hayek T, Keidar S, Mei Y, Oiknin J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis in apo E deficient mice. Circulation 1995;92:2998.
40. Maor I, Hayek T, Coleman R, Aviram M. Plasma LDL oxidation leads to its aggregation in the atherosclerotic apo E deficient mice. Arterioscler Thromb 1997;17:2995-3005.
41. Tangirala R, Casanada F, Miller E, Witztum J, Steinberg D, Palinski W. Effect of the antioxidant N,N′-diphenyl-1,4-phenylenediamine (DPPD) on atherosclerosis in apo E deficient mice. Arterioscler Thromb Vasc Biol 1995;15:1625-30.